Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction
Robert J. Mentz(Duke University), Christopher M. O’Connor(Inova Health System), Thomas G. von Lueder(Oslo University Hospital), Mona Fiuzat(Duke University), Carolyn S.P. Lam(University of Glasgow), Ewa A. Jankowska(Wroclaw Medical University), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Dan Atar, Javed Butler(Saint Luke's Health System), Martín Cowie(National Institutes of Health), Keld Kjeldsen(Aalborg University Hospital), Jacob P. Kelly(Duke University), Adriaan A. Voors(University Medical Center Groningen), Bertram Pitt(Bayer (Germany))
Cited by 541
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k